Novimmune Sells Gamifant And IO Assets To Sobi

Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).

merger and acquisition business concepts, join company on puzzle pieces, 3d rendering
Sobi Bolts On Former Novimmune Assets

Novimmune SA has a sold a newly created vehicle comprising Gamifant (emapalumab) and related assets, two additional immune-oncology candidates and an FDA priority review voucher to Sweden’s Swedish Orphan Biovitrum AB for CHF515m ($519m). The acquisition comes less than a year after Novimmune granted Sobi an exclusive worldwide license for Gamifant. The acquisition fits in Sobi's sweet spot for rebalancing its portfolio and enhancing its immunology activities [Sidebar#SC125391].

Specifically, Sobi is gaining access to all assets relating to Gamifant, including intellectual property, patent rights, data and know-how, all...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip